Loading...
XTSE
MDNA
Market cap41mUSD
Jul 15, Last price  
0.83CAD
1D
0.00%
1Q
-17.00%
IPO
-69.26%
Name

Medicenna Therapeutics Corp

Chart & Performance

D1W1MN
No data to show
P/E
36.86
P/S
EPS
0.02
Div Yield, %
Shrs. gr., 5y
22.09%
Rev. gr., 5y
%
Revenues
0k
Net income
2m
P
00-1,334,064-7,631,265-7,465,452-4,708,031-8,309,340-17,183,000-22,646,0001,547,000
CFO
-13m
L-46.33%
00-2,570,915-7,305,328-10,124,352-8,037,005-8,954,401-15,311,000-23,584,000-12,657,000
Earnings
Jul 29, 2025

Profile

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
IPO date
Jul 13, 2015
Employees
16
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
16,298
Unusual Expense (Income)
NOPBT
(16,298)
NOPBT Margin
Operating Taxes
(11,595)
Tax Rate
NOPAT
(4,703)
Net income
1,547
-106.83%
Dividends
Dividend yield
Proceeds from repurchase of equity
24,760
BB yield
-43.46%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(33,596)
Cash flow
Cash from operating activities
(12,657)
CAPEX
Cash from investing activities
Cash from financing activities
24,760
FCF
(4,468)
Balance
Cash
33,596
Long term investments
Excess cash
33,596
Stockholders' equity
20,000
Invested Capital
12,646
ROIC
ROCE
EV
Common stock shares outstanding
64,736
Price
0.88
-46.67%
Market cap
56,968
-36.40%
EV
23,372
EBITDA
(16,294)
EV/EBITDA
Interest
Interest/NOPBT